| Hazard Information | Back Directory | [Uses]
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity[1][2]. | [in vivo]
Ecnoglutide (0.015, 0.15 mg/kg, s.c., a single time) reduces blood glucose, promotes insulin induction, and leads to more pronounced body weight reduction compared to Semaglutide (HY-114118) in db/db mice[2].
Ecnoglutide (1 mg/kg, s.c., rats) shows the T1/2 (h), Tmax (h), Cmax (nM), AUClast (h*nM), MRT (h) values of 11.7, 18 .0, 387.3, 16274.8, 25.4 respectively[2].
| [References]
[1] WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.
[2] Guo W, et al. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023 Sep;75:101762. DOI:10.1016/j.molmet.2023.101762 |
|
| Company Name: |
Chinapeptide
|
| Tel: |
15295566865 15295566865 |
| Website: |
http://www.synpeptide.cn |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
www.biorbyt.com |
|